No Data
Sanyuan Biological (301206.SZ): The company currently has no plans to acquire a starch enterprise.
According to Gelonghui on December 6, San Yuan Biology (301206.SZ) stated on the investor interaction platform that the company maintains long-term stable cooperation with multiple starch enterprises within the province, which can fully meet the current production needs. As of now, the company has no plans to acquire starch enterprises. If there are related matters, the company will strictly fulfill its information disclosure obligations according to laws and regulations.
Sanyuan Bio (301206.SZ): has repurchased a total of 0.26% of shares.
On December 2, Gelonghui announced that as of November 30, 2024, Sanyuan Bioscience (301206.SZ) disclosed that the company repurchased a total of 525,700 shares through a share buyback dedicated account in a centralized competitive bidding trading method, accounting for 0.26% of the total share capital. The highest fill price was 27.78 yuan per share, the lowest fill price was 23.70 yuan per share, and the total fill amount was 12.9113 million yuan (excluding transaction costs).
Sanyuan Biological (301206.SZ): Currently has a production capacity of 10,000 tons of allulose per year.
On November 27, Gelonghui reported that Three Trees Bioscience (301206.SZ) stated on the investor interaction platform that the company currently has an annual production capacity of 10,000 tons of allose, which can well meet the diversified market demand.
Solid Earnings Reflect Shandong Sanyuan BiotechnologyLtd's (SZSE:301206) Strength As A Business
San Yuan Biology (301206.SZ): The chairman's shareholding plan has been fully implemented.
On November 4th, Gehlunhui announced that as of the disclosure date of this announcement, the controlling shareholder, actual controller, and chairman Mr. Nie Zaijian have cumulatively increased the company's shares by 352,600 shares through centralized bidding, accounting for 0.1747% of the company's current total share capital (excluding 525,700 shares in the company's repurchase dedicated securities account). The amount of the shareholding was 9,062,378 yuan (excluding fees), and the shareholding plan has been completed.
Sanyuan Biotech: Report for the third quarter of 2024
No Data
